Problem att logga in eller att hålla dig inloggad? Klicka här
Första gången du loggar in: Välj att antingen logga in med din e-post och använd ditt medlemsnummer som lösenord eller Beställ nytt lösenord för att logga in på webbplatsen.
Har du inget konto än? BLI MEDLEM HÄR
On the basis of the approval by the Annual General Meeting on 20 April 2022 to authorize the Board of Targovax ASA to issue new shares to employees under the Company long-term...
Oslo, Norway, 3 November 2022 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today annou...
Oslo, Norway, 26 October 2022 - Targovax ASA (OSE: TRVX) will announce its third quarter 2022 results on Thursday 3 November 2022. Targovax's management will present the ...
Oslo, Norway, 18 August 2022 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announ...
Oslo, 4 July 2022: Targovax ASA (the "Company") is pleased to announce that the drop-down demerger approved by the general meeting of the Company on 20 April 2022 ha...
Oslo, 7 June 2022: Reference is made to the stock exchange announcement by Targovax ASA (OSE:TRVX) ("Targovax" or the "Company") on 31 May 2022, regarding ...
Oslo, 31 May 2022: Reference is made to the stock exchange announcement published by Targovax ASA (the "Company") on 31 May 2022 regarding the settlement of RSUs and...
Oslo, 31 May 2022: The board of directors of Targovax ASA (OSE:TRVX) ("Targovax" or the "Company") has resolved to increase the share capital of the Compan...
Oslo, Norway, 12 May 2022 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces...
Reference is made to the annual general meeting of Targovax ASA (the "Company") on 20 April 2022 (the "AGM") where election of members to the board of dire...
The annual general meeting was held on 20 April 2022 at the Company's offices at Vollsveien 19, 1366 Lysaker.
Please find minutes of the meeting attached:
The Annual General Meeting of Targovax ASA (the "Company") will be held at the Company's offices at Lysaker, on 20 April 2022 at 16:00 CET.
Notice of ...
Lysaker, 14 March 2022: The Board of Directors of Targovax has today, on 14 March 2022, signed a joint demerger and merger plan, respectively, for the transfer of the operatio...
On 9 March 2022, the Board of Directors of Targovax ASA approved the Company's Annual Report, including the financial statements for 2021, which will be processed at the ...
Oslo, 8 March 2022: Reference is made to the stock exchange announcement by Targovax ASA ("Targovax" or the "Company") on 2 March 2022, regarding the board...
Oslo, 7 March 2022: Reference is made to the announcement made by Targovax ASA ("Targovax" or the "Company") 28 February 2022 regarding the appointment of ...
Reference is made to the stock exchange announcement published by Targovax ASA (the "Company") on 2 March 2022 regarding exercise of options under LTI program, settl...
Oslo, 2 March 2022: The board of directors of Targovax ASA (OSE:TRVX) ("Targovax" or the "Company") has resolved to increase the share capital of the Compa...
Oslo, Norway, 28 February 2022 - Targovax ASA (OSE: TRVX) a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today ann...